Latest

Therapeutic Focus: Rare Diseases

Therapeutic Focus: Rare Diseases

The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

Hysingla ER is ready for the marketplace, just two months after FDA approval.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

P&G's Zzzquil accused of sexist tweet

The nighttime sleep aid's Twitter account wrote "Sleep LIKE he finally proposed," last week, a sentiment which didn't resonate positively with the feed's followers.

Drugmaker enlists Fitbit to better understand patients

Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

NPS drug approval bolsters Shire acquisition decision

NPS drug approval bolsters Shire acquisition decision

The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

Agency Spotlight


This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters